Search

Policy & advocacy

Our mandateEHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders.

Read more

EHA response to the EU’s Pharma Revision

Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation. In April 2023, the European Commission published a proposed Directive and Regulation to replace the current, outdated legal framework.

Read more

EHA-SWG Scientific Meeting on Pediatric Hematology 2022

On April 7-9, 2022 the EHA-SWG Scientific Meeting on Pediatric Hematology was successfully held at the NH Collection Vittorio Veneto hotel in Rome.

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

Acute Myeloid Leukemia

The AML SWG represents a group of national and internationally renowned clinical and research experts working in the field of AML.

Read more

Meet Maria-Victoria Mateos, our April Volunteer of the Month

Maria Victoria Mateos currently heads the Scientific Program Committee of the 24th EHA Congress which will be held on June 13-16 in Amsterdam.

Read more

Meet Maria-Victoria Mateos, our April Volunteer of the Month

Maria Victoria Mateos currently heads the Scientific Program Committee of the 24th EHA Congress which will be held on June 13-16 in Amsterdam.

Read more